Search
Captopril
go.drugbank.com/drugs/DB01197ApprovedInvestigationalCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the r...
Categories: P-glycoprotein inhibitorsZopiclone
go.drugbank.com/drugs/DB01198ApprovedInvestigationalZopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbitu...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesFomepizole
go.drugbank.com/drugs/DB01213ApprovedVet approvedFomepizole is used as an antidote in confirmed or suspected methanol or ethylene glycol poisoning. Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 InhibitorsAnastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigationalAnastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to e...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Be...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersQuetiapine
go.drugbank.com/drugs/DB01224ApprovedInvestigationalInitially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT inte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEncainide
go.drugbank.com/drugs/DB01228ApprovedWithdrawnAll drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent hea...
Synonyms: (±)-2'-[2-(1-methyl-2-piperidyl)ethyl]-p-anisanilideCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesSaquinavir
go.drugbank.com/drugs/DB01232ApprovedInvestigationalSaquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the ...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsChlorprothixene
go.drugbank.com/drugs/DB01239ApprovedInvestigationalWithdrawnChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Categories: P-glycoprotein inhibitors